Goldman Sachs
EBS icon

Goldman Sachs’s Emergent Biosolutions EBS Stock Holding History

Goldman Sachs’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-45,000
Closed -$1.26M – 7044
2016
Q2 		$1.26M Sell
45,000
-3,100
-6% -$122K ﹤0.01% 3996
2016
Q1 		$1.75M Buy
+48,100
New +$1.7M ﹤0.01% 3607

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Goldman Sachs's EBS Position: Q2 2026 in Review

Goldman Sachs increased its Emergent Biosolutions (EBS) stake by 28% in Q2 2026, buying an estimated $1.87M and bringing the position to 1,035,421 shares worth $8.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3374.

Goldman Sachs first reported a position in EBS in Q2 2013 and has held it in 53 quarters since. The position peaked at $80.7M in Q4 2020. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Goldman Sachs held 1,035,421 shares of Emergent Biosolutions worth $8.68M as of Q2 2026.
  • Goldman Sachs bought 223,861 Emergent Biosolutions shares in Q2 2026, an estimated $1.87M.
  • Emergent Biosolutions made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3374 holding.
  • Goldman Sachs first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's Emergent Biosolutions position peaked at $80.7M in Q4 2020.
  • 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.